Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-355: Pembrolizumab + Chemotherapy in TNBC
NCT02819518Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2016
- Primary completion
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Merck & Co.. Started Jul 2016; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02819518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819518.